Hasil Pencarian (2)
biotech | CAS: 1418205-77-2
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.[L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F.[A244455] It…
Kategori:
Agents reducing cytokine levelsAmino Acids, Peptides, and ProteinsAntibodies
+11
Target Protein:
Interleukin-17AInterleukin-17F
Waktu ParuhThe mean terminal e…
Vol. DistribusiIn patients with pl…
KlirensThe median apparent…
Genetik
-
biotech | CAS: 1229022-83-6
Secukinumab is a fully human monoclonal IgG1/? antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis.[L39600] By blocking the actions of IL-17A, sec…
Kategori:
Agents reducing cytokine levelsAmino Acids, Peptides, and ProteinsAntibodies
+14
Target Protein:
Interleukin-17A
Waktu ParuhThe half-life range…
Vol. DistribusiThe mean volume of …
KlirensThe mean systemic c…
Genetik
-